The therapeutic role of ivabradine in heart failure-Reference-Cited by-同舟云学术

The therapeutic role of ivabradine in heart failure

Published:2018-07-04 Issue:11 Volume:9 Page:199-207
ISSN:2040-6223
Container-title:Therapeutic Advances in Chronic Disease
language:en
Short-container-title:Therapeutic Advances in Chronic Disease

Author:

Badu-Boateng Charles¹,Jennings Robert¹,Hammersley Daniel²

Affiliation:

1. Department of Medicine, Frimley Park Hospital, Frimley, Camberley, UK

2. Department of Cardiology, Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK

Abstract

Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (If) inhibitor, which acts on the sinoatrial node, resulting in a reduction in heart rate. Ivabradine is currently licensed for use in patients with symptomatic heart failure with reduced ejection fraction and a heart rate persistently at least 70 beats per minute in spite of otherwise optimal prognostic heart failure pharmacotherapy. In this review article, we examine the mechanism of action of ivabradine, evaluate the clinical trials underpinning its application in heart failure and discuss its current recommended clinical use in this capacity.

Publisher

SAGE Publications

Subject

Medicine (miscellaneous)

Link

http://journals.sagepub.com/doi/pdf/10.1177/2040622318784556

Reference53 articles.

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2. Clinical epidemiology of heart failure

3. Ivabradine for chronic heart failure?

4. The patient with left ventricular systolic dysfunction now and in the future

5. Heart Disease and Stroke Statistics—2016 Update

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies;Cells;2024-09-01

2. Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium;Heart Failure Reviews;2024-06-29

3. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials;Quantitative Imaging in Medicine and Surgery;2024-02

4. The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2023-10-17

5. The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review;Cureus;2023-09-21